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.ABSTRACT
There is increasing evidence that terlipressin is useful in patients with cirrhosis and 
hepatorenal syndrome, but there are no data of its use in patients with acute liver 
failure  (ALF)  in  whom  hepatorenal  syndrome  is  common.  Although  terlipressin 
produces  systemic  vasoconstriction,  it  produces  cerebral  vasodilatation  and  may 
increase  cerebral  blood  flow  (CBF).  Increased  CBF  contributes  to  intracranial 
hypertension in patients with ALF. The aim of this study was to evaluate the safety of 
terlipressin  in  patients  with  ALF  with  respect  to  cerebral  haemodynamics.  Six 
successive  patients  with  ALF  were  electively  ventilated  for  grade  IV  hepatic 
encephalopathy. Patients were monitored invasively and CBF was measured (Kety-
Schmidt technique). Measurements were made before, at 1, 3 hour and 5 hours after 
intravenous (single bolus) administration of terlipressin (0.005 mg/kg) )intravenously 
(single bolus), median 0.25mg (range 0.2-0.3). There was no significant change in 
heart rate, mean arterial pressure or cardiac output. CBF and jugular venous oxygen 
saturation  both  increased  significantly  at  1  hour  (p<0.0=0.016)  respectively. 
Intracranial pressure increased significantly at 21 hours (p<0=.0.031), returning back 
to baseline values at 42 hours. This study shows that administration of terlipressin, at 
a  dose  that  did  not  alter  systemic  haemodynamicshemodynamics,  resulted  in 
worsening of cerebral hyperemia and intracranial hypertension in patients with ALF 
and severe hepatic encephalopathy. These data suggest the need to exercise extreme 
caution in the use of terlipressin in these patients in view of its potentially deleterious 
consequences on cerebral haemodynamics.INTRODUCTION
Acute liver failure (ALF) is characterisedcharacterized by rapid deterioration in the 
level of  consciousness, and a mortality rate of about 90% in patients who fulfill 
criteria  for  poor  prognosis.1 In  the  later  stages  of  encephalopathy,  elevation  in 
intracranial  pressure  (ICP)  is  common  due  to  the  development  of  cerebral 
oedemaedema. The exact pathogenic mechanism of the increased ICP is unknown but 
current literature suggestspports a two-multiple hit hypothesis in which ammonia is 
thought to be central; a central role for ammonia with a later increase in cerebral 
blood flow (CBF) accentuating the rise in ICP.2-4 Studies in a portacaval shunted rats 
administered an ammonia load have demonstrated a rise in CBF that paralleled the 
increase in ICP and correlated directly with the brain water content.5,6 In the later 
stages of ALF, but before intracranial hypertension is manifest, cerebral hyperemia 
often prevails and seems to precede herniation.7,8 Cerebral hyperemia is therefore of 
crucial importance in the development of increased ICP in ALF.
Normal  cerebral  vascular  resistance  is  essential  for  the  maintenance  of  cerebral 
autoregulation. Reactive vasodilatation or vasoconstriction ensures constant cerebral 
perfusion.9 In patients with ALF, autoregulation is impaired, but can be restored if 
cerebral  arteriolar  tone  is  increased  by  hyperventilation,  suggesting  that  cerebral 
vasodilatation is responsible for the impairment in autoregulation.510 In patients with 
ALF, a reduction in CBF results in a decrease in ICP.11
The mechanism of the increased CBF has to be examined in relation to the 
generalized  circulatory  disturbance  which  is  characterised  by  tachycardia, 
hypotension,  increased  cardiac  output  and  peripheral  vasodilatation  which  may 
contribute to the occurrence of hepatorenal syndrome in ALF. Hepatorenal syndrome 
develops in approximately 55% of all patients referred to specialized units with ALF and frequently these patients require renal support. 126-8  - 14
Terlipressin, is an inactive vasopressin analogue, which is slowly metabolized in vivo 
to its active form, lysine vasopressin. It has been used to treat norepinephrine-resistant 
hypotension when associated with septic shock 9 and there is an increasing body of 
evidence that it may be useful in patients with cirrhosis and hepatorenal syndrome. 10-
14
 has been used to treat norepinephrine-resistant hypotension when associated 
with septic shock 15 and there is an increasing body of evidence that it may be useful 
in  patients  with  cirrhosis  and  hepatorenal  syndrome.16-20 Vasopressin  is  a  potent 
systemic vasoconstrictor, thought to exert its effects through peripheral V1 receptors. 
In animal studies, the administration of vasopressin however, also increases CBF by 
dilating cerebral arteries. 15-17 21-23 Vasopressin may also regulate regional CBF by two 
balancing  the  effects  of  increased  flow  mediated  by  nitric  oxide  release  from  the 
endothelium, andwith decreased flow in vessels contracted by direct stimulation of 
smooth muscle. 2184 It has been postulated that the increase in CBF may be mediated 
through cerebral V2 receptors. 19 In a preliminary report, vasopressin administration in 
an animal model of ALF and cerebral oedemaedema resulted in worse brain swelling. 
25
As  hepatorenal  syndrome  and  systemic  hypotension  are  common  in  patients  with 
ALF, terlipressin may be a useful drug for the management of these complications. 
However, gGiven the distribution of the vasopressin V2 receptors in the brain it is 
possible that terlipressin may accentuate cerebral hyperemia and worsen intracranial 
hypertension in ALF. Our justification for aims in performing this small study wasere
to evaluate whether terlipressin has any deleterious effect on cerebral haemodynamics 
prior to proceeding to aconducting a suitable randomized controlled trial of the use of 
terlipressin in patients with hepatorenal syndrome in ALF. In this study, we evaluated the effect of administration of terlipressin at a sub-therapeutic dose to patients with 
ALF and Grade IV hepatic encephalopathy and measured serial changes in systemic 
haemodynamics, ICP and CBF.
METHODS
Studies were undertaken at The Transplant Unit at the Royal Infirmary of Edinburgh 
between June and December 1999. with the aApproval was obtainedof by the local 
Lothian rResearch eEthics cCommittee and  and wwritten informed consent assent 
was obtained from the next of kin of each patient in accordance with the Declaration 
of Helsinki (1989) of the World Medical Association.Study Design. 6Six, successive unselected patients with ALF were enrolled into the 
study with ALF. Patients had been admitted to the Intensive Care Unit with Grade IV 
hepatic encephalopathy were included into the study. and had cardiovascular and ICP 
monitors inserted. Patients were excluded if they required inotropic support or any 
specific  treatment  for  elevated  ICP  prior  to  entry  into  the  study.  Cardiovascular 
haemodynamics, ICP, jugular venous oxygen saturation (JVOS), CBF and blood gases 
were measured prior to and then for 5 hours after administration of 0.005 mg/Kg of 
terlipressin  [median  0.25  mg  (range  0.2  - 0.3  mg)]  as  a  single  intravenous  bolus 
(terlipressin acetate injection, Ferring Pharmaceuticals). This low dose was chosen to 
prevent significant changes in the systemic haemodynamics so as to allow assessment 
of changes in CBF irrespective of the changes in MAP.
Patients. We studied 6 patients with ALF (median age, 27 (22-46) years, 4 females, 
etiology: paracetamolacetaminophen: 4, acute fatty liver of pregnancy:1: 1, non A, 
non B viral:1: 1) and 4 fulfilled the Kings College Criteria for poor prognosis.1 The 
median  concentration  of  serum  bilirubin  was  156  ([range  102-345)]  µmol/L, 
prothrombin  time  67  (range  [49-123)]  sec,  plasma  lactate  4.5  (range  [2.9- 6.9])
mmol/L,  arterial  ammonia  212  ([167-311)  ]µmol/L  and  the  arterial  pH  was 7.32 
([7.20-7.43).]  Median  serum  creatinine  was  312  (range  [189-365)]  µmol/L  and  4 
patients  required  renal  support  with  continuous  veno-venous  haemofiltration  for 
hepatorenal syndrome. Haemofiltration was started prior to and continued throughout 
the duration of the study.
Monitoring  and  Measurements.  All  the  patients  were  mechanically  ventilated 
following
sedation with propofol. ICP was continuously monitored in 5 of the patients using a 
subdural fibre-optic system (Camino, Camino Laboratories, San Diego, USA). The ICP  value  recorded  was  theat  value  obtained  was  recorded  at  hourly  intervals. 
Cardiovascular  haemodynamics  were  monitored  continuously  with  a  Swan-Ganz 
catheter (Edwards Lifesciences, Irvine, CA). Heart rate, MAP and cardiac output were 
recorded at hourly intervals. 
Measurement of cerebral blood flow and jugular venous oxygen saturation. In 
order to measure cerebral blood flow (CBF), an arterial catheter was inserted into the 
femoral artery and a jugular bulb catheter was inserted into the left internal jugular 
vein  (4F  Opticath,  U440,  Abbot,  USA).  Correct  positioning  of  the  jugular  bulb 
catheter was confirmed with a lateral head and neck radiograph.2620 Cerebral venous 
monitoring via a jugular bulb catheter allows assessment of global oxygen delivery 
adequacy  and  does  not  exacerbate  intracranial  hypertension.  2127 Jugular  venous 
oxygen saturation (JVOS) was monitored continuously via the reverse jugular catheter 
and recorded hourly. CBF was only determined if the patient was hemodynamically 
stable, defined as a difference variation of less than 10% in the mean arterial pressure. 
Ventilation  was  adjusted  to  achieve  an  arterial  carbon  dioxide  tension  of  4-4.5 
kiloPascals  (kPa),  and  was  not  altered  again  during  the  study  to  prevent  PaCO2
becoming a confounding factor of CBF. Modification of the Kety-Schmidt technique 
2822 was used to measure CBF which is dependent on the rate of uptake of nitrous 
oxide by the brain as detailed previously.239 Measurements were made prior to and 
then after 1 and 5 hours following the administration of terlipressin. 
Statistics. Data are expressed as median and range. Differences in measured variables 
over between individual time points for acid base status and systemic haemodynamics 
after administration of terlipressin was calculated using the Wilcoxon Signed Rank 
test.a one-way ANOVA with Bonferroni post correction. Significance was accepted at 
p<0.05.Differences in the cerebrovascular haemodynamics were also calculated using the  Wilcoxon  Signed  Rank  test.using  repeated  measures  one-way  ANOVA  with 
Bonferroni post correction. RESULTS
Patients.  Three  of  the  four  patients  who  fulfilled  criteria  for  poor  prognosis, 
underwent
successful OLT a median of 46 ([37-67])  hours after admission to the intensive care 
unit. The 4th patient, who had psycho-socialpsychosocial contraindications to OLT, 
died 4 days after admission to the intensive care unit with multiorgan failure. The 
other two patients recovered without need for OLT and could be discharged from the 
intensive care unit 73 and 84 hours, respectively, after first presentation with Grade IV 
encephalopathy.
Cardiovascular  Haemodynamics.  As  shown  in  Table  1,  all  patients  showed 
evidence of a hyperdynamic circulation with increased cardiac output and heart rate 
and  reduced  MAP  and  systemic  vascular  resistance.  Following  administration  of 
terlipressin there was minimal increase in the MAP (Figure 1a) and systemic vascular 
resistance and, an insignificant reduction in cardiac output and heart rate, but none of 
these  changes  were  either  clinically  or  statistically  significant. An  increase  in 
hydrogen  ion  concentration  was  found  to  be  significant  at  5  hours  following 
terlipressin (p=0.031), though this corresponds to a change in arterial pH from 7.41 to 
7.39, which was not thought to be clinically relevant as both values remain within 
normal limits. There were no other significant changes in the central venous pressure 
or the arterial blood gases found (Table 1).
Cerebrovascular Haemodynamics. There was a significant increase in CBF from a 
median  of  69  ([range  48-83)]  ml/100g/min  to  81  (range  [62-97])  ml/100g/min  (p<0.001=0.016), 1 hour after administration of terlipressin (Figure 1c). The values CBF 
remained significantly higher at 3 hours following terlipressin administration, but at 
retuned to baseline values at 5 hours after terlipressin administration were similar to 
had returned to baseline values; 70 (53-95) ml/100g/min. This was associated with an 
increase in ICP in all patients from a median of 15 (range[ 113-18]) mmHg to 20 
(range [16-23)] mmHg (p=0.031<0.01) after 1 hour, becoming maximal at 2 hours 
with  median  of  22  (range  15-23)  mmHg  (p<0.001).  The  rise  in  ICP  remained 
significant  at  3  hours,  with  median  18  (14-23)  (Figure  1b),  returning  to  baseline 
values at 42 hours. In keeping with the increased CBF, the JVOS increased from a 
median  of  75%  (range  [67-89)]  to  87%  (range  [75-94)]  (p=0.016<0.001)  1  hour 
afterwards and remained significantly elevated high but returned to values that were 
similar to the baseline values by for 3 hours,  returning, returning to baseline values at 
5 hours 80% ([66-90]) (Figure 1d).DISCUSSION.
This  study  demonstrates  that  administration  of  low  dose  terlipressin  produces  no 
significant changes in systemic haemodynamics, but is associated with increases in 
CBF and a resultant increase in ICP, suggesting the need for extreme caution in the 
use of this drug in patients with ALF and with grade IV hepatic encephalopathy. 
Increased ICP and brain herniation is a major cause of mortality in patients 
with ALF if this is not controlled by repeated mannitol treatments and ultrafiltration.1
Although the pathogenesis of increased ICP in ALF is not entirely clear, At the time 
this study was planned (1998), there was increasing concern that increased CBF may 
underlie the pathogenesis of increased ICP in patients with ALF. In particular, data 
from Aggarwal et al. 24 showed that those patients with high ICP have elevated CBF. 
Since then, there has been is an increasing body of literature suggesting a crucial role 
for  cerebral  hyperemia  as  being  critical  in  the  development  of  intracranial 
hypertension in ALF. Data supporting the above are derived from observations in experimental animals  2,3,5,6 and also from studies in patients with ALF. Studies in 
portacaval shunted rats administered an ammonia load have demonstrated a rise in 
CBF  that  paralleled  the  increase  in  ICP  and  correlated  directly  with  brain  water 
content. 25,26, 26 Cerebral hyperemia is of crucial importance in the development of 
increased  ICP  in  ALF.  Normal  cerebral  vascular  resistance  is  essential  for  the 
maintenance of cerebral autoregulation. Reactive vasodilatation or vasoconstriction 
ensures constant cerebral perfusion.27 When modalities are introduced to control the 
rise in CBF, such as methionine-sulfoxamine (an inhibitor of glutamine synthase) 25
and mild hypothermia 28, ammonia-induced cerebral edema is prevented. It has also 
been shown that the cerebral vasoconstrictor, indomethacin, blunts the rise in CBF in 
portacaval shunted rats receiving an ammonia load and that the consequent reduction 
in CBF leads to a disproportionate reduction of ammonia uptake by the brain which 
may reduce brain edema. 29
7, 10,30,31 Experiments  in  portacaval  shunted  rats  given  ammonia  infusion 
develop  cerebral  oedemaedema  which  is  preceded  by  increases  in  CBF.5,6
Furthermore,  the  rise  in  ICP  parallels  the  increase  in  CBF.  When  modalities  are 
introduced to control the rise in CBF, such as methionine-sulfoamine (an inhibitor of 
glutamine  synthase)  5 and  mild  hypothermia  32,  ammonia  -induced  cerebral 
oedemaedema is prevented. It has also been shown that the cerebral vasoconstrictor, 
indomethacin, blunts the rise in CBF in portacaval shunted rats receiving an ammonia 
load and that the consequent reduction in CBF leads to a disproportionate reduction of 
ammonia  uptake  by  the  brain  which  may  reduce  brain  oedemaedema.  33 Direct 
evidence for the role of cerebral hyperemia being important in the pathogenesis of 
increased ICP has been derived from studies in patients with ALF, that have shown 
that an increase in CBF, induced by an increase a rise in MAP, was associated with an increase  in  ICP.3304 The  rise  in  ICP  did  not  occur  if  the  cerebral  hyperemia  was 
prevented from occurring using hypothermia. 1130,31, 314 Although data in humans are 
variable, they support the notion that increased CBF is crucial in the pathogenesis of 
increased ICP.  5,,  7,8,10,30-,31,343 Indeed, in the present study the increaserise in CBF 
induced by terlipressin resulted was associated inwith an increase in ICP.
The  loss  of  CBF  autoregulation  is  likely  to  be  mediated  through  cerebral 
vasodilatation.354 However,  the  increase  in  CBF  following  administration  of 
terlipressin is unlikely to have occurred due to a loss of reflect the effects of altered 
CBF autoregulation because administration of terlipressin was not associated with any 
significant  changes  in  the  mean  arterial  pressure  and  therefore  cerebral  perfusion 
pressure.  In  addition,  the  effects  of  a  low  dose  bolus  of  terlipressin  on  CBF  and 
consequent  ICP  were  of  short  duration  and  completely  reversible,  with  all  values 
returning  to  baseline  values  at  5  hours  which  is  entirely  consistent  with  the 
pharmacokinetics of terlipressin which has a half-life of 50 minutes. 35
The exact mechanism by which terlipressin leads to an increase in CBF cannot 
be elucidated from this study but we postulate that it is likely to be mediated through 
cerebral  V2  receptors.  If  the  effect  had  been  preferentially  mediated  through  V1 
receptors,  then  we  would  have  expected  a  rise  in  MAP  due  to  its  peripheral 
vasoconstrictor effects, which was not the case in this study. The results of a recent 
study  by  Chung  et  al.  36 using  an  experimental  animal  model  of  cerebral  edema 
(ammonia infusion following portacaval anastomosis), demonstrated that vasopressin 
administration results in an increase in CBF and worsening of brain edema support 
this  suggestion.  They  observed  an  increase  in  CBF  when  vasopressin  was 
administered  both  in  the  presence  of  V1  and  V2  receptor  anatagonists.  With  V1 
receptor antagonism the increase in CBF following vasopressin occurred without a simultaneous increase in the MAP indicating a V2 receptor dependent mechanism, as 
was observed in our study. Importantly, they also observed that the animals that were 
treated  with  vasopressin  had  higher  ammonia  concentrations.  Although  the  exact 
mechanism of this hyperammonemia is not clear, it may represent reduced perfusion 
of critical ammonia removing organs.
In  addition,  the  effects  of  a  low  dose  bolus  of  terlipressin  on  CBF  and 
consequent  ICP  were  of  short  duration  and  completely  reversible,  with  all  values 
returning  to  baseline  values  at  5  hours  which  is  entirely  consistent  with  the 
pharmacokinetics of terlipressin with a half-life of 50 minutes. 36
Evidence for increased brain nitric oxide in ALF exists in studies of animal 
models of ALF, where enhanced brain flux of nitric oxide has been demonstrated 
through increased expression of neuronal nitric oxide synthase.37 It has been shown in 
rats that the increased brain uptake of L-arginine resulting from portacaval shunting 
results in a 2 fold increase in neuronal nitric oxide synthase protein expression and a 
concomitant 2.4 fold increase in neuronal nitric oxide synthase messenger RNA.38
Increased neuronal nitric oxide synthase activity in the brain and the resulting nitric 
oxide production could contribute to the increased CBF.
In conclusion, the results of this study suggest that administration of even a 
single sub-therapeutic dose of terlipressin to patients with ALF and grade IV hepatic 
encephalopathy  may  have  deleterious  consequences  through  worsening  of  cerebral 
hyperemia and intracranial hypertension. The aeffect of terlipressin on CBF in patients 
with ALF and low -mild grade hepatic encephalopathy however, cannot be ascertained 
from  the  results  of  this  study.  Consideration  of  these  findings  suggests  that  it  is 
unwise proceed with the use of terlipressin in a large scale clinical trial at this time. 
Thiisese data suggestss that extreme caution should be exercised and close monitoring is  required  if  this  drug  is  used  in  patients  with  ALF  and  severe  hepatic 
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LEGENDS TO FIGUREFigure  1.  Changes  in  (a)  mean  arterial  pressure  (MAP);  (b)  intracranial  pressure 
(ICP);  (c)  cerebral  blood  flow  (CBF);  and  (d)  jugular  venous  oxygen  saturation 
(JVOS) prior to and after administration of 0.005 mg/Kg of terlipressin intravenously.
Individual patients are represented: Patient 1 represented by filled diamonds ♦, (♦); 
patient 2( by open squares □),; patient 3 by filled triangles (▲),; patient 4 by filled 
squares( ■),; patient 5 filled circles( ●); and patient 6 open circles( ○). P-values were 
calculated  using  the  Repeated  repeated  measures  one-  way  ANOVA  with  a
Bonferonni  post  test  Bonferonni  correction.Wilcoxon  Signed  Rank  test. ([Normal 
values (used by authorsauthor’s institution)] :]: MAP 93 - 100 mmHg, CBF 45 - 50 
ml/100g/min, ICP 0 -15 mmHg, JVOS 55 -75 %).Table 1. Acid-base status and Systemic haemodynamics after administration of 
0.005 mg/Kg of Terlipressin intravenously.